The ET market is expanding due to improved diagnostic methods and therapeutic innovations. Key players including Novartis, Incyte, and PharmaEssentia are developing targeted JAK inhibitors and cytoreductive therapies that better control thrombotic risk and disease symptoms. Advancements in molecular testing and treatment guidelines are enabling more personalized management approaches for this chronic myeloproliferative neoplasm. View Market Report: https://shorturl.at/QyAgR